Regn

Electromed: A Closer Look at What Lies Beyond the Immediate Horizon

Corvus Pharmaceuticals Takes Key Step Forward with Lead Eczema Drug

Regeneron's Remarkable Resurgence: Charting the Course of a Biotech Comeback

CRISPR Therapeutics: Beyond the Hype, A Foundational Investment in Gene Editing's Future

Regeneron and Tessera Forge Potent Alliance for Next-Generation Gene Editing Therapies

A Bold Bet on the Future: Regeneron's $150M Investment in Gene Writing

A Fresh Look at Regeneron: Why Analysts Are Seeing Significant Upside

Regeneron's Remarkable Q3: A Dupixent-Driven Triumph That Reaffirms Biotech's Pulse

The Anticipation Builds: Kymera's Big Bet on Better Skin Could Be a Game-Changer

The Intelligent Pivot: How Savvy Acquisitions Are Forging a New Path to Profitability

The Biotech Bonanza: Unearthing Tomorrow's Investment Gems in a Volatile Market

Trump's Bold Vision: Pushing for Direct Drug Deals to Slash Costs

Regeneron's Evkeeza Achieves Landmark FDA Approval, Extending Life-Saving Treatment to Youngest HoFH Patients

Historic Shift: White House Reviews Landmark Drug Price Negotiation Rule

Regeneron's Growth Horizon: Beyond the Core, Towards New Frontiers

A Beacon of Hope: Regeneron's Pozelimab Shines in Ultra-Rare Genetic Disorder Study

A New Chapter for Ophthalmology: Regeneron and Sandoz Resolve Landmark Eylea Patent Battle

First RSV shots, groundbreaking gene therapy among 2024 drugs to watch